Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022

Rhea-AI Summary

Concert Pharmaceuticals (NASDAQ: CNCE) will announce its third quarter 2022 financial results on November 7, 2022, before U.S. markets open. A conference call and webcast will be held at 8:30 a.m. ET for discussion of the results and business updates. Interested parties can register for the live call here. An audio webcast will be available on the company’s website, with a replay accessible for three months.

Concert Pharmaceuticals is focused on developing deuruxolitinib (CTP-543), a novel JAK1/2 inhibitor, having completed two Phase 3 trials for alopecia areata.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update.

To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call.

An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005054/en/

Justine Koenigsberg

(781) 674-5284

ir@concertpharma.com

Source: Concert Pharmaceuticals, Inc.

FAQ

When will Concert Pharmaceuticals report its Q3 2022 financial results?

Concert Pharmaceuticals will report its Q3 2022 financial results on November 7, 2022, before U.S. markets open.

What time is the conference call for Concert Pharmaceuticals' Q3 2022 results?

The conference call for Concert Pharmaceuticals' Q3 2022 results will be held at 8:30 a.m. ET on November 7, 2022.

How can I join the Q3 2022 earnings call for Concert Pharmaceuticals?

You can join the Q3 2022 earnings call by registering here.

Is there a replay available for the Concert Pharmaceuticals earnings call?

Yes, a replay of the Concert Pharmaceuticals earnings call will be available on their website for three months.

What is the focus of Concert Pharmaceuticals' development?

Concert Pharmaceuticals is focused on developing deuruxolitinib (CTP-543), a JAK1/2 inhibitor for alopecia areata.